LYEL vs. ALEC, ERAS, VERV, BCYC, ALLO, FOLD, MOR, IDYA, MRVI, and DYN
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Alector (ALEC), Erasca (ERAS), Verve Therapeutics (VERV), Bicycle Therapeutics (BCYC), Allogene Therapeutics (ALLO), Amicus Therapeutics (FOLD), MorphoSys (MOR), IDEAYA Biosciences (IDYA), Maravai LifeSciences (MRVI), and Dyne Therapeutics (DYN). These companies are all part of the "medical" sector.
Lyell Immunopharma (NASDAQ:LYEL) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, community ranking, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.
In the previous week, Lyell Immunopharma had 1 more articles in the media than Alector. MarketBeat recorded 2 mentions for Lyell Immunopharma and 1 mentions for Alector. Alector's average media sentiment score of 1.87 beat Lyell Immunopharma's score of 0.62 indicating that Alector is being referred to more favorably in the news media.
Alector has a net margin of -125.11% compared to Lyell Immunopharma's net margin of -335,794.09%. Lyell Immunopharma's return on equity of -33.92% beat Alector's return on equity.
Alector received 133 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 60.58% of users gave Alector an outperform vote while only 56.52% of users gave Lyell Immunopharma an outperform vote.
Lyell Immunopharma has a beta of -0.54, suggesting that its share price is 154% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.
Lyell Immunopharma presently has a consensus target price of $5.50, indicating a potential upside of 98.56%. Alector has a consensus target price of $14.00, indicating a potential upside of 184.55%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Alector is more favorable than Lyell Immunopharma.
66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 25.1% of Lyell Immunopharma shares are held by insiders. Comparatively, 9.1% of Alector shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Alector has higher revenue and earnings than Lyell Immunopharma. Alector is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Alector beats Lyell Immunopharma on 12 of the 18 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
